Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Nov;19(5):343-53.
doi: 10.2165/00002018-199819050-00002.

Post-marketing studies: the work of the Drug Safety Research Unit

F J Mackay  1
Affiliations

Post-marketing studies: the work of the Drug Safety Research Unit

F J Mackay. Drug Saf. 1998 Nov.

Abstract

The Drug Safety Research Unit (DSRU) is the centre for prescription-event monitoring (PEM) in England. PEM studies are noninterventional observational cohort studies which monitor the safety of newly marketed drugs. The need for post-marketing surveillance is well recognised in the UK and general practice is an ideal source of data. PEM studies are general practitioner (community)-based and exposure is based on dispensed prescription data in England. To date, 65 PEM studies have been completed with a mean cohort size of 10 979 patients and the DSRU database has clinical information on over 700000 patients prescribed new drugs. Unlike spontaneous reporting schemes, PEM produces incidence rates for events reported during treatment. Comparative studies can be conducted for drugs in the same class. The DSRU aggregates outcome data for pregnancies exposed to new drugs. Data for children and the elderly can also be specifically examined. PEM data have a number of advantages over data from computerised general practice databases in the UK. PEM is the only technique within the UK capable of monitoring newly marketed drugs in such a comprehensive and systematic way.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Drug Saf. 1997 Jun;16(6):355-65 - PubMed
    1. BMJ. 1998 Jan 31;316(7128):343-5 - PubMed
    1. Br J Clin Pharmacol. 1993 Jun;35(6):599-602 - PubMed
    1. Br Med J (Clin Res Ed). 1988 Feb 6;296(6619):399-400 - PubMed
    1. BMJ. 1996 Sep 21;313(7059):732-3; discussion 733-4 - PubMed

Publication types

-